The integration of the DMA-CPP system with cytochrome C represents a novel approach, aiming to enhance the targeted delivery and efficacy of the bioactive protein within cancer cells, leveraging the acidic tumour microenvironment to trigger a therapeutic response. Here, CYCS is linked to cancer.